Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant
暂无分享,去创建一个
Michael Busby | Jason J. Davis | P. Ko Ferrigno | Qifeng Song | S. Wagner | Anthony T Buxton | L. Stadler | T. Hoffmann | Michael Busby | Qifeng Song | Lukas Kurt Josef Stadler | Paul Ko Ferrigno | Toni Hoffmann | Anthony T. Buxton | Simon D. Wagner | Toni Hoffmann
[1] M. K. Shaw,et al. Synthesis of Macromolecules by Escherichia coli near the Minimal Temperature for Growth , 1967, Journal of bacteriology.
[2] G. Caponigro,et al. Green fluorescent protein as a scaffold for intracellular presentation of peptides. , 1998, Nucleic acids research.
[3] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.
[4] Andreas Plückthun,et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.
[5] A. Barrett,et al. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. , 1986, The Journal of biological chemistry.
[6] D. Craik,et al. Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design. , 2006, The Biochemical journal.
[7] Steven Johnson,et al. Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays , 2008, Journal of biology.
[8] 大房 健. 基礎講座 電気泳動(Electrophoresis) , 2005 .
[9] I. Björk,et al. The role of the second binding loop of the cysteine protease inhibitor, cystatin A (stefin A), in stabilizing complexes with target proteases is exerted predominantly by Leu73. , 2002, European journal of biochemistry.
[10] L. Wilkinson. Immunity , 1891, The Lancet.
[11] Jan Tkac,et al. Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold. , 2007, Analytical chemistry.
[12] R. Ladner,et al. Constrained peptides as binding entities. , 1995, Trends in biotechnology.
[13] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[14] R. Jerala,et al. Accessing the global minimum conformation of stefin A dimer by annealing under partially denaturing conditions. , 1999, Journal of molecular biology.
[15] T. Prasthofer,et al. Characterization by spectroscopic, kinetic and equilibrium methods of the interaction between recombinant human cystatin A (stefin A) and cysteine proteinases. , 1995, The Biochemical journal.
[16] S. Laurenson,et al. Design and validation of a neutral protein scaffold for the presentation of peptide aptamers. , 2005, Journal of molecular biology.
[17] P. van Endert,et al. Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. , 2002, Molecular immunology.
[18] W. Bode,et al. The 2.0 A X‐ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. , 1988, The EMBO journal.
[19] R. Huber,et al. The refined 2.4 A X‐ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. , 1990, The EMBO journal.
[20] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[21] J. Mccoy,et al. A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in the E. coli Cytoplasm , 1993, Bio/Technology.
[22] A. Plückthun,et al. Designed to be stable: Crystal structure of a consensus ankyrin repeat protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] Kees Jalink,et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. , 2003, Immunity.
[24] A. Koide,et al. The fibronectin type III domain as a scaffold for novel binding proteins. , 1998, Journal of molecular biology.
[25] Jason J. Davis,et al. Peptide aptamers in label-free protein detection: 2. Chemical optimization and detection of distinct protein isoforms. , 2009, Analytical chemistry.
[26] M. Kainosho,et al. Solution structure of a human cystatin A variant, cystatin A2-98 M65L, by NMR spectroscopy. A possible role of the interactions between the N- and C-termini to maintain the inhibitory active form of cystatin A. , 1995, Biochemistry.
[27] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.
[28] V. Turk,et al. Protein inhibitors of cysteine proteinases. III. Amino-acid sequence of cystatin from chicken egg white. , 1983, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[29] Arne Skerra,et al. Anticalins as an alternative to antibody technology , 2005, Expert opinion on biological therapy.
[30] I. Björk,et al. The contribution of N-terminal region residues of cystatin A (stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B, and cathepsin L. , 1999, Biochemistry.
[31] Steven Johnson,et al. Surface-immobilized peptide aptamers as probe molecules for protein detection. , 2008, Analytical chemistry.
[32] M. Uhlén,et al. A combinatorial library of an α-helical bacterial receptor domain , 1995 .
[33] H. Kolmar. Alternative binding proteins: Biological activity and therapeutic potential of cystine‐knot miniproteins , 2008, The FEBS journal.
[34] C. Fisher,et al. Modification of a PCR-based site-directed mutagenesis method. , 1997, BioTechniques.
[35] J. Waltho,et al. Comparison of backbone dynamics of monomeric and domain‐swapped stefin A , 2004, Proteins.
[36] J. Waltho,et al. The role of Gly-4 of human cystatin A (stefin A) in the binding of target proteinases. Characterization by kinetic and equilibrium methods of the interactions of cystatin A Gly-4 mutants with papain, cathepsin B, and cathepsin L. , 1998, Biochemistry.
[37] V. Turk,et al. Major differences in stability and dimerization properties of two chimeric mutants of human stefins , 2001, Proteins.
[38] J. Thompson,et al. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.
[39] V. Turk,et al. Human cystatin, a new protein inhibitor of cysteine proteinases. , 1984, Biochemical and biophysical research communications.
[40] B. Lenarčič,et al. Folding studies of the cysteine proteinase inhibitor--human stefin A. , 1991, Biochimica et biophysica acta.
[41] J. Waltho,et al. The three-dimensional solution structure of human stefin A. , 1995, Journal of molecular biology.
[42] P. Colas. The eleven-year switch of peptide aptamers , 2008, Journal of biology.
[43] A. Skerra. Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.
[44] T. Mulhern,et al. Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold. , 2006, Protein engineering, design & selection : PEDS.
[45] R. Brent,et al. An artificial cell-cycle inhibitor isolated from a combinatorial library. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] Wenmiao Shu,et al. Highly specific label-free protein detection from lysed cells using internally referenced microcantilever sensors. , 2008, Biosensors & bioelectronics.
[47] Torsten Schwede,et al. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling , 2006, Bioinform..
[48] 김삼묘,et al. “Bioinformatics” 특집을 내면서 , 2000 .
[49] J. Waltho,et al. Structural characterisation of human stefin A in solution and implications for binding to cysteine proteinases. , 1994, European journal of biochemistry.
[50] C Marque,et al. Human abdominal EHG processing for uterine contraction monitoring. , 1989, Biotechnology.
[51] A. Barrett,et al. Cystatin-like cysteine proteinase inhibitors from human liver. , 1984, The Biochemical journal.
[52] N. Bryan,et al. Cardioprotective effects of thioredoxin in myocardial ischemia and the reperfusion role of S-nitrosation , 2004 .
[53] Roger Brent,et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 , 1996, Nature.
[54] F. Hoppe-Seyler,et al. Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding , 2002, Cellular and Molecular Life Sciences CMLS.
[55] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.
[56] 유영제,et al. Biotechnology에서 배우는 교훈 , 2006 .
[57] D. Turk,et al. Crystal structure of Stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo- and exopeptidases. , 2003, Journal of molecular biology.
[58] Debjani Paul,et al. Label-free detection of protein interactions with peptide aptamers by open circuit potential measurement , 2008 .
[59] H. Kolmar,et al. Alternative binding proteins get mature: Rivalling antibodies , 2008, The FEBS journal.
[60] Manuel C. Peitsch,et al. SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..
[61] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[62] P. Ferrigno,et al. A peptide aptamer to antagonize BCL-6 function , 2006, Oncogene.
[63] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[64] Eric Beitz,et al. TeXshade: shading and labeling of multiple sequence alignments using LaTeX2e , 2000, Bioinform..
[65] Andreas Plückthun,et al. Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. , 2008, Journal of molecular biology.